Werewolf Therapeutics (NASDAQ:HOWL) Stock Breaks Below Fifty Day Moving Average – Should You Sell?

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) shares passed below its 50 day moving average during trading on Tuesday. The stock has a 50 day moving average of $0.98 and traded as low as $0.97. Werewolf Therapeutics shares last traded at $0.97, with a volume of 217,807 shares changing hands.

Analyst Upgrades and Downgrades

HOWL has been the subject of a number of recent analyst reports. Weiss Ratings upgraded shares of Werewolf Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, September 10th. Zacks Research lowered shares of Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 3rd. Finally, Wall Street Zen raised shares of Werewolf Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 22nd. Two analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $4.00.

Werewolf Therapeutics Price Performance

The stock has a market cap of $47.14 million, a price-to-earnings ratio of -1.28 and a beta of 0.55. The stock has a fifty day moving average of $0.98 and a 200 day moving average of $0.70.

Hedge Funds Weigh In On Werewolf Therapeutics

A number of institutional investors have recently bought and sold shares of HOWL. Covestor Ltd purchased a new stake in shares of Werewolf Therapeutics in the 3rd quarter valued at $124,000. Bank of America Corp DE acquired a new stake in shares of Werewolf Therapeutics in the second quarter worth $112,000. Vontobel Holding Ltd. purchased a new position in shares of Werewolf Therapeutics during the third quarter worth $55,000. StoneX Group Inc. raised its holdings in shares of Werewolf Therapeutics by 174.3% during the third quarter. StoneX Group Inc. now owns 54,856 shares of the company’s stock worth $51,000 after purchasing an additional 34,856 shares during the last quarter. Finally, Vilga Financial Planning LLC purchased a new position in shares of Werewolf Therapeutics during the third quarter worth $49,000. 64.84% of the stock is owned by hedge funds and other institutional investors.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing cancer treatments that stimulate the immune system. The company’s approach is designed to activate immune responses within the tumor microenvironment while limiting exposure to healthy tissues. Werewolf’s technology platform, known as INDUKINE, uses conditionally activated cytokines. These therapeutic proteins are intended to remain inactive in the bloodstream and become activated primarily in tumors, where they may help recruit and enhance immune cells to attack cancer.